Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | RARA | P10276 | 2/20 | 0.35 |
| ▸ | RARB | P10826 | 2/20 | 0.35 |
| ▸ | RARG | P13631 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047058 | 1.00 | HNF4A (0.37) | HNF4ARXRACXCL12RARARARB | |
| SCHEMBL5047068 | 0.93 | MAOB (0.42) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL5047064 | 0.93 | MAOB (0.42) | MAPTNPC1RAB9AKMT2A | |
| SCHEMBL5047057 | 0.89 | RARA (0.46) | HNF4ARXRARARARARBRARG | |
| SCHEMBL5047062 | 0.89 | RARA (0.46) | HNF4ARXRARARARARBRARG | |
| SCHEMBL5050772 | 0.85 | RARA (0.43) | HNF4ARXRARARARARBRARG | |
| SCHEMBL5050776 | 0.85 | RARA (0.43) | HNF4ARXRARARARARBRARG | |
| SCHEMBL5049636 | 0.83 | RARA (0.38) | HNF4ARXRACXCL12RARARARB | |
| SCHEMBL5049635 | 0.83 | RARA (0.38) | HNF4ARXRACXCL12RARARARB | |
| SCHEMBL5047066 | 0.82 | AKR1C3 (0.42) | CXCL12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | HNF4A 876/4885RXRA 4/4885CXCL12 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.